Lunai Bioworks Inc.
11/03/2025 | Press release | Distributed by Public on 11/03/2025 15:32
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
An annual meeting of our shareholders was held on October 31, 2025 (the "Annual Meeting"). At the Annual Meeting, our shareholders voted on each of the following four matters:
| 1. | To elect four directors to serve until the Company's 2026 annual meeting of stockholders or until their successors are duly elected and qualified ("Election of Directors"); |
| 2. | To approve by a non-binding advisory vote the compensation of the Company's named executive officers, as disclosed in this proxy statement (the "Say-on-Pay Proposal"); |
| 3. | To approve by a non-binding advisory vote the appointment of Sadler, Gibb & Associates LLC ("Sadler") as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026 (the "Auditor Ratification Proposal"); and |
| 4. | To approve proposed amendments to the Renovaro Biosciences, Inc. 2023 Equity Incentive Plan, as amended, in substantially the form attached to the proxy statement as Annex A (the "Incentive Plan Proposal"). |
According to the final vote, the Company's stockholders approved proposals 1, 2, 3, and 4.
The final vote results for each of these four matters is set forth below.
Proposal 1: Election of Eight Directors
| For | Withheld | Broker Non-Vote1 | ||||||||||
| David Weinstein | 7,539,245 | 202,737 | - | |||||||||
| James McNulty | 7,368,045 | 373,937 | - | |||||||||
| Douglas W. Calder | 7,343,710 | 398,272 | - | |||||||||
| Mark A, Collins | 7,368,381 | 373,601 | - | |||||||||
1 The Company received a total of 1,314, 903 Broker Non-Votes, which were not broken down for each director
The election of directors described above was conducted in accordance with the applicable requirements of Nasdaq Listing Rule 5605(e), which governs the process for the election of directors and requires that a majority of the board's members be independent directors as defined in Nasdaq Listing Rule 5605(a)(2). The Company further confirms that the director nomination and election process complied with all applicable Nasdaq corporate governance standards, including those relating to the composition and independence of the Nominating and Corporate Governance Committee under Rule 5605(e)(1) and the shareholder approval and voting requirements under Rule 5620. The election of directors at the Annual Meeting was duly conducted and is in compliance with Nasdaq's corporate governance and voting standards.
Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2026 annual meeting of stockholders.
Proposal 2: Approval of Say-on-Pay Proposal
| For: | 5,548,091 | |||
| Against: | 2,182,131 | |||
| Abstain: | 11,760 | |||
| Broker Non-Vote | 1,314,903 |
Accordingly, stockholders approved by a non-biding advisory vote the compensation of the Company's named executive officers.
Lunai Bioworks Inc. published this content on November 03, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 03, 2025 at 21:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]